Isofol participates in several investor meetings in December and January
Non regulatory
European Patent Office intends to grant a new patent for Isofol’s arfolitixorin
Non regulatory
Isofol Medical AB (publ) publishes interim report, January–September 2025
Regulatory
Isofol appoints nomination committee ahead of the Annual General Meeting 2026
Regulatory
Isofol invites to an investor meeting on November 13, 2025
Non regulatory
Isofol participates in the ESMO cancer congress
Non regulatory
Isofol’s clinical study with arfolitixorin reaches another important milestone
Non regulatory
Isofol completes transfer of shares to Solasia Pharma following a successful rights issue
Non regulatory
Isofol Medical AB (publ) publishes interim report, January–June 2025
Regulatory
Isofol invites to a presentation of the interim report for the second quarter 2025
Non regulatory
New number of shares and votes in Isofol
Regulatory
Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin
Non regulatory
Isofol’s rights issue fully subscribed – exercises overallotment for Japanese partner
Regulatory
Isofol publishes prospectus in connection with the company’s rights issue
Regulatory
Isofol completes first cohort in ongoing clinical study with arfolitixorin
Non regulatory
